{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:35:06Z","timestamp":1777541706119,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Adenomyosis is a chronic uterine disorder characterised by ectopic endometrial tissue within the myometrium, frequently associated with dysmenorrhea, abnormal uterine bleeding (AUB), chronic pelvic pain (CPP), and dyspareunia. No standardised guidelines are currently available for its management, and therapeutic options remain limited for women seeking fertility preservation. This study aimed to evaluate the efficacy of intravaginal progesterone in alleviating adenomyosis-related symptoms in patients seeking fertility preservation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective monocentric observational study, 85 patients aged 22\u201350\u00a0years with ultrasound-confirmed symptomatic adenomyosis were enrolled between April 2020 and April 2024. Inclusion criteria were age 18\u201355\u00a0years, BMI 18\u201335, and a Visual Analogue Scale (VAS) score\u2009\u2265\u20097 for dysmenorrhea, AUB, CPP, or dyspareunia. All patients received 200\u00a0mg\/day of intravaginal progesterone for 10\u00a0days per cycle. Symptom severity was assessed using VAS scores at baseline and at 6\u00a0months. Data were analysed using non-parametric statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-five patients completed the 6-month follow-up. Four patients conceived during treatment and were excluded from the final analysis. Statistically significant improvements were observed for all assessed symptoms (all p\u2009&lt;\u20090.05). Median VAS scores decreased for dysmenorrhea (9 to 6, p\u2009&lt;\u20090.001), AUB (8 to 6, p\u2009&lt;\u20090.001), chronic pelvic pain (5.5 to 3.5, p\u2009&lt;\u20090.001), and dyspareunia (2 to 0, p\u2009=\u20090.020). The overall treatment satisfaction was high, with a mean Likert score of 7.5 out of 10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravaginal progesterone appears to be an effective fertility-sparing treatment for symptomatic adenomyosis, providing significant relief across all primary symptoms, with high patient satisfaction. Larger controlled studies are warranted to confirm these preliminary findings and further define its role in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08361-y","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:21:33Z","timestamp":1777396893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravaginal progesterone as a fertility-sparing treatment for symptomatic adenomyosis: preliminary results from a monocentric study"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-8494","authenticated-orcid":false,"given":"Carlo","family":"De Cicco Nardone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9653-7821","authenticated-orcid":false,"given":"Maria Cristina","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7923-1647","authenticated-orcid":false,"given":"Gian Mario","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-5616","authenticated-orcid":false,"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-0035","authenticated-orcid":false,"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-7014","authenticated-orcid":false,"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-4318","authenticated-orcid":false,"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2231-8506","authenticated-orcid":false,"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"8361_CR1","first-page":"33","volume":"105","author":"S Schrager","year":"2022","unstructured":"Schrager S, Yogendran L, Marquez CM, Sadowski EA (2022) Adenomyosis: diagnosis and management. Am Fam Physician 105:33\u201338","journal-title":"Am Fam Physician"},{"key":"8361_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/22840265241248488","author":"P Tragantzopoulou","year":"2024","unstructured":"Tragantzopoulou P (2024) Endometriosis and stigmatization: a literature review. J Endometr Pelvic Pain Disord. https:\/\/doi.org\/10.1177\/22840265241248488","journal-title":"J Endometr Pelvic Pain Disord"},{"key":"8361_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/uog.26159","volume":"62","author":"I Mishra","year":"2023","unstructured":"Mishra I, Melo P, Easter C et al (2023) Prevalence of adenomyosis in women with subfertility: systematic review and meta-analysis. Ultrasound Obstet Gynecol 62:23\u201341. https:\/\/doi.org\/10.1002\/uog.26159","journal-title":"Ultrasound Obstet Gynecol"},{"key":"8361_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154407","volume":"11","author":"M Sztachelska","year":"2022","unstructured":"Sztachelska M, Ponikwicka-Tyszko D, Mart\u00ednez-Rodrigo L et al (2022) Functional implications of estrogen and progesterone receptors expression in adenomyosis, potential targets for endocrinological therapy. J Clin Med 11:4407. https:\/\/doi.org\/10.3390\/jcm11154407","journal-title":"J Clin Med"},{"key":"8361_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.fertnstert.2023.03.006","volume":"119","author":"SE Bulun","year":"2023","unstructured":"Bulun SE, Yildiz S, Adli M et al (2023) Endometriosis and adenomyosis: shared pathophysiology. Fertil Steril 119:746\u2013750. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.03.006","journal-title":"Fertil Steril"},{"key":"8361_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00404-013-3049-8","volume":"289","author":"H Kobayashi","year":"2014","unstructured":"Kobayashi H, Yamada Y, Morioka S et al (2014) Mechanism of pain generation for endometriosis-associated pelvic pain. Arch Gynecol Obstet 289:13\u201321. https:\/\/doi.org\/10.1007\/s00404-013-3049-8","journal-title":"Arch Gynecol Obstet"},{"key":"8361_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.fertnstert.2018.01.013","volume":"109","author":"S Vannuccini","year":"2018","unstructured":"Vannuccini S, Luisi S, Tosti C et al (2018) Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 109:398\u2013405. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.01.013","journal-title":"Fertil Steril"},{"key":"8361_CR8","unstructured":"(2024) US Medical Eligibility Criteria for Contraceptive Use, 2016 (US MEC) | CDC. https:\/\/www.cdc.gov\/reproductivehealth\/contraception\/mmwr\/mec\/summary.html. Accessed 24 June 2024"},{"key":"8361_CR9","first-page":"1304","volume-title":"Medication adherence and contraceptive counseling","author":"MI de Molina-Fernandez","year":"2023","unstructured":"de Molina-Fernandez MI, Reyes-Mart\u00ed L, De la Flor-L\u00f3pez M et al (2023) Medication adherence and contraceptive counseling, vol 11. Healthcare, p 1304"},{"key":"8361_CR10","volume-title":"StatPearls","author":"DB Cooper","year":"2024","unstructured":"Cooper DB, Patel P (2024) Oral contraceptive pills. StatPearls. StatPearls Publishing, Treasure Island"},{"key":"8361_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bpobgyn.2016.09.006","volume":"40","author":"JA Abbott","year":"2017","unstructured":"Abbott JA (2017) Adenomyosis and abnormal uterine bleeding (AUB-A)-pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol 40:68\u201381. https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.09.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"8361_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0010-7824(95)00210-2","volume":"52","author":"T Luukkainen","year":"1995","unstructured":"Luukkainen T, Toivonen J (1995) Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 52:269\u2013276. https:\/\/doi.org\/10.1016\/0010-7824(95)00210-2","journal-title":"Contraception"},{"key":"8361_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01957-7","volume":"83","author":"A Etrusco","year":"2023","unstructured":"Etrusco A, Barra F, Chiantera V et al (2023) Current medical therapy for adenomyosis: from bench to bedside. Drugs 83:1595. https:\/\/doi.org\/10.1007\/s40265-023-01957-7","journal-title":"Drugs"},{"key":"8361_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196130","volume":"12","author":"G Moawad","year":"2023","unstructured":"Moawad G, Youssef Y, Fruscalzo A et al (2023) The present and the future of medical therapies for adenomyosis: a narrative review. J Clin Med 12:6130. https:\/\/doi.org\/10.3390\/jcm12196130","journal-title":"J Clin Med"},{"key":"8361_CR15","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3109\/00016340903280982","volume":"88","author":"L Rode","year":"2009","unstructured":"Rode L, Langhoff-Roos J, Andersson C et al (2009) Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand 88:1180\u20131189. https:\/\/doi.org\/10.3109\/00016340903280982","journal-title":"Acta Obstet Gynecol Scand"},{"key":"8361_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ajog.2017.11.576","volume":"218","author":"R Romero","year":"2018","unstructured":"Romero R, Conde-Agudelo A, Da Fonseca E et al (2018) Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a\u00a0short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 218:161\u2013180. https:\/\/doi.org\/10.1016\/j.ajog.2017.11.576","journal-title":"Am J Obstet Gynecol"},{"key":"8361_CR17","doi-asserted-by":"crossref","unstructured":"Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH (2018) Progestogen for treating threatened miscarriage|Cochrane Library","DOI":"10.1002\/14651858.CD005943.pub5"},{"key":"8361_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.rbmo.2018.02.001","volume":"36","author":"T Child","year":"2018","unstructured":"Child T, Leonard SA, Evans JS, Lass A (2018) Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online 36:630\u2013645. https:\/\/doi.org\/10.1016\/j.rbmo.2018.02.001","journal-title":"Reprod Biomed Online"},{"key":"8361_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bpobgyn.2020.05.004","volume":"69","author":"M Jewson","year":"2020","unstructured":"Jewson M, Purohit P, Lumsden MA (2020) Progesterone and abnormal uterine bleeding\/menstrual disorders. Best Pract Res Clin Obstet Gynaecol 69:62\u201373. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.05.004","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"8361_CR20","unstructured":"Checklists. In: STROBE. https:\/\/www.strobe-statement.org\/checklists\/. Accessed 24 June 2024"},{"key":"8361_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ijgo.14946","volume":"162","author":"V Jain","year":"2023","unstructured":"Jain V, Munro MG, Critchley HOD (2023) Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO systems 1 and 2. Int J Gynaecol Obstet 162:29\u201342. https:\/\/doi.org\/10.1002\/ijgo.14946","journal-title":"Int J Gynaecol Obstet"},{"key":"8361_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.14331","volume":"159","author":"MG Munro","year":"2022","unstructured":"Munro MG, Balen AH, Cho S et al (2022) The FIGO ovulatory disorders classification system. Int J Gynaecol Obstet 159:1\u201320. https:\/\/doi.org\/10.1002\/ijgo.14331","journal-title":"Int J Gynaecol Obstet"},{"key":"8361_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/uog.14806","volume":"46","author":"T den Van Bosch","year":"2015","unstructured":"den Van Bosch T, Dueholm M, Leone FPG et al (2015) Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol 46:284\u2013298. https:\/\/doi.org\/10.1002\/uog.14806","journal-title":"Ultrasound Obstet Gynecol"},{"key":"8361_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/uog.24786","volume":"60","author":"MJ Harmsen","year":"2022","unstructured":"Harmsen MJ, den Van Bosch T, de Leeuw RA et al (2022) Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. Ultrasound Obstet Gynecol 60:118\u2013131. https:\/\/doi.org\/10.1002\/uog.24786","journal-title":"Ultrasound Obstet Gynecol"},{"key":"8361_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/13468","volume":"22","author":"C Escalona-Marfil","year":"2020","unstructured":"Escalona-Marfil C, Coda A, Ruiz-Moreno J et al (2020) Validation of an electronic visual analog scale mHealth tool for acute pain assessment: prospective cross-sectional study. J Med Internet Res 22:e13468. https:\/\/doi.org\/10.2196\/13468","journal-title":"J Med Internet Res"},{"key":"8361_CR26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"BMJ"},{"key":"8361_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1571727","volume":"16","author":"A Etrusco","year":"2025","unstructured":"Etrusco A, Agrifoglio V, D\u2019Amato A et al (2025) Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol 16:1571727. https:\/\/doi.org\/10.3389\/fendo.2025.1571727","journal-title":"Front Endocrinol"},{"key":"8361_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/rmb2.12408","volume":"20","author":"I Ota","year":"2021","unstructured":"Ota I, Taniguchi F, Ota Y et al (2021) A controlled clinical trial comparing potent progestins, LNG\u2010IUS and dienogest, for the treatment of women with adenomyosis. Reprod Med Biol 20:427\u2013434. https:\/\/doi.org\/10.1002\/rmb2.12408","journal-title":"Reprod Med Biol"},{"key":"8361_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2025.2511329","volume":"41","author":"S Vannuccini","year":"2025","unstructured":"Vannuccini S, La Torre F, Toscano F et al (2025) Medical treatment for adenomyosis: long term use of progestins. Gynecol Endocrinol 41:2511329. https:\/\/doi.org\/10.1080\/09513590.2025.2511329","journal-title":"Gynecol Endocrinol"},{"key":"8361_CR30","first-page":"96","volume":"44","author":"MP Warren","year":"1999","unstructured":"Warren MP, Shantha S (1999) Uses of progesterone in clinical practice. Int J Fertil Womens Med 44:96\u2013103","journal-title":"Int J Fertil Womens Med"},{"key":"8361_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147989","volume":"23","author":"L Kolatorova","year":"2022","unstructured":"Kolatorova L, Vitku J, Suchopar J et al (2022) Progesterone: a steroid with wide range of effects in physiology as well as human medicine. Int J Mol Sci 23:7989. https:\/\/doi.org\/10.3390\/ijms23147989","journal-title":"Int J Mol Sci"},{"key":"8361_CR32","volume-title":"StatPearls","author":"M Tayyeb","year":"2025","unstructured":"Tayyeb M, Gupta V (2025) Dyspareunia. StatPearls. StatPearls Publishing, Treasure Island"},{"key":"8361_CR33","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.3390\/ijms222011039","volume":"22","author":"B Nagy","year":"2021","unstructured":"Nagy B, Szekeres-Barth\u00f3 J, Kov\u00e1cs GL et al (2021) Key to life: physiological role and clinical implications of progesterone. Int J Mol Sci 22:11039. https:\/\/doi.org\/10.3390\/ijms222011039","journal-title":"Int J Mol Sci"},{"key":"8361_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.15537\/smj.2020.4.25036","volume":"41","author":"ES Alsulmi","year":"2020","unstructured":"Alsulmi ES, Alfaraj M, Faden Y, Al Qahtani N (2020) The use of progesterone during pregnancy to prevent preterm birth. Saudi Med J 41:333\u2013340. https:\/\/doi.org\/10.15537\/smj.2020.4.25036","journal-title":"Saudi Med J"},{"key":"8361_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajog.2019.12.006","volume":"223","author":"A Coomarasamy","year":"2020","unstructured":"Coomarasamy A, Devall AJ, Brosens JJ et al (2020) Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol 223:167\u2013176. https:\/\/doi.org\/10.1016\/j.ajog.2019.12.006","journal-title":"Am J Obstet Gynecol"},{"key":"8361_CR36","doi-asserted-by":"publisher","first-page":"e943400-1","DOI":"10.12659\/MSM.943400","volume":"30","author":"T-J Lai","year":"2024","unstructured":"Lai T-J, Teng S-W, Chang C-K, Huang C-Y (2024) Progesterone in pregnancy: evidence-based strategies to reduce miscarriage and enhance assisted reproductive technology. Med Sci Monit 30:e943400-1-e943400-9. https:\/\/doi.org\/10.12659\/MSM.943400","journal-title":"Med Sci Monit"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08361-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08361-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08361-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:21:38Z","timestamp":1777396898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08361-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8361"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08361-y","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki; informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"177"}}